Cumin F, Evin G, Fehrentz JA, Seyer R, Castro B, Menard J, et al. Inhibition of human renin by synthetic peptides derived from its prosegment. J Biol Chem. 1985;260:9154–7.
Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Investig. 2002;109:1417–27.
Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006;69:105–13.
Saris JJ, t Hoen PA, Garrelds IM, Dekkers DH, den Dunnen JT, Lamers JM, et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension. 2006;48:564–71.
Campbell DJ, Kladis A, Skinner SL, Whitworth JA. Characterization of angiotensin peptides in plasma of anephric man. J Hypertens. 1991;9:265–74.
Nussberger J, de Gasparo M, Juillerat L, Guyenne TT, Mooser V, Waeber B, et al. Rapid measurement of total and active renin: plasma concentrations during acute and sustained converting enzyme inhibition with CGS 14824A. Clin Exp Hypertens. 1987;9:1353–66.
CAS Google Scholar
Morris BJ. Activation of human inactive (“pro-“) renin by cathepsin D and pepsin. J Clin Endocrinol Metab. 1978;46:153–7.
Osmond DH, Cooper RM. Cryoactivation and tryptic activation of blood ‘prorenin’ in normal man and animals. Can J Physiol Pharm. 1978;56:792–805.
Krop M, Lu X, Danser AH, Meima ME. The (pro)renin receptor. A decade of research: what have we learned? Pflug Arch. 2013;465:87–97.
Franken AA, Derkx FH, Man in’t Veld AJ, Hop WC, van Rens GH, Peperkamp E, et al. High plasma prorenin in diabetes mellitus and its correlation with some complications. J Clin Endocrinol Metab. 1990;71:1008–15.
Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem. 1991;37:1811–9.
Campbell DJ, Nussberger J, Stowasser M, Danser AH, Morganti A, Frandsen E, et al. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem. 2009;55:867–77.
Derkx FH, de Bruin RJ, van Gool JM, van den Hoek MJ, Beerendonk CC, Rosmalen F, et al. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem. 1996;42:1051–63.
Toffelmire EB, Slater K, Corvol P, Menard J, Schambelan M. Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal humans. Studies using a direct immunoradiometric assay. J Clin Investig. 1989;83:679–87.
Krop M, van Gool JM, Day D, Hollenberg NK, Jan, Danser AH. Evaluation of a direct prorenin assay making use of a monoclonal antibody directed against residues 32-39 of the prosegment. J Hypertens. 2011;29:2138–46.
Morish*ta Y, Hanawa S, Miki T, Sugase T, Sugaya Y, Chinda J, et al. The association of plasma prorenin level with an oxidative stress marker, 8-OHdG, in nondiabetic hemodialysis patients. Clin Exp Nephrol. 2011;15:398–404.
Pringle KG, Sykes SD, Lumbers ER. Circulating and intrarenal renin-angiotensin systems in healthy men and nonpregnant women. Physiol Rep. 2015;3:e12586.
Sykes SD, Pringle KG, Zhou A, Dekker GA, Roberts CT, Lumbers ER. Fetal sex and the circulating renin-angiotensin system during early gestation in women who later develop preeclampsia or gestational hypertension. J Hum Hypertens. 2014;28:133–9.
Fujimoto K, Hayashi A, Kamata Y, Ogawa A, Watanabe T, Ichikawa R, et al. Circulating levels of human salusin-β, a potent hemodynamic and atherogenesis regulator. PLoS ONE. 2013;8:e76714.
Suzuki N, Shichiri M, Tateno T, Sato K, Hirata Y. Distinct systemic distribution of salusin-α and salusin-β in the rat. Peptides. 2011;32:805–10.
Fujimoto K, Hayashi A, Kodera Y, Saito T, Toki T, Ogawa A, et al. Identification and quantification of plasma free salusin-β, an endogenous parasympathomimetic peptide. Sci Rep. 2017;7:8275.
Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem. 2003;75:663–70.
Taguchi T, Kodera Y, Oba K, Saito T, Nakagawa Y, Kawashima Y, et al. Suprabasin-derived bioactive peptides identified by plasma peptidomics. Sci Rep. 2021;11:1047.
Tani Y, Yamada S, Inosh*ta N, Hirata Y, Shichiri M. Regulation of growth hormone secretion by (pro)renin receptor. Sci Rep. 2015;5:10878.
Yoshino S, Fujimoto K, Takada T, Kawamura S, Ogawa J, Kamata Y, et al. Molecular form and concentration of serum α2-macroglobulin in diabetes. Sci Rep. 2019;9:12927.
Kawashima Y, f*ckutomi T, Tomonaga T, Takahashi H, Nomura F, Maeda T, et al. High-yield peptide-extraction method for the discovery of subnanomolar biomarkers from small serum samples. J Proteome Res. 2010;9:1694–705.
Saito T, Kawashima Y, Minamida S, Matsumoto K, Araki K, Matsui T, et al. Establishment and application of a high-quality comparative analysis strategy for the discovery and small-scale validation of low-abundance biomarker peptides in serum based on an optimized novel peptide extraction method. J Electrophoresis. 2013;57:1–9.
Toki T, Kodera Y, Konno R, Hirata Y, Saito T, Shichiri M. A novel strategy to identify autoantigens by proteomic analysis of plasma IgG-bound proteins. J Electrophoresis. 2019;63:15–24.
Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Met. 2012;9:671–5.
Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens. 2004;22:377–81.
Morganti A, Pelizzola D, Mantero F, Gazzano G, Opocher G, Piffanelli A. Immunoradiometric versus enzymatic renin assay: results of the Italian Multicenter Comparative Study. Italian Multicenter Study for Standardization of Renin Measurement. J Hypertens. 1995;13:19–26.
Bardsley EN, Neely OC, Paterson DJ. Angiotensin peptide synthesis and cyclic nucleotide modulation in sympathetic stellate ganglia. J Mol Cell Cardiol. 2020;138:234–43.
Danser AH, Derkx FH, Schalekamp MA, Hense HW, Riegger GA, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens. 1998;16:853–62.
Naruse M, Wasada T, Naruse K, Yoshimoto T, Omori Y, Demura H. Pathophysiological significance of plasma total renin and prorenin in patients with diabetes mellitus. Endocr J. 1995;42:225–33.
Schumacher M, Nanninga A, Delfs T, Mukhopadhyay AK, Leidenberger FA. A direct immunoradiometric assay for human plasma prorenin: concentrations in cycling women and in women taking oral contraceptives. J Clin Endocrinol Metab. 1992;75:617–23.
CAS PubMed Google Scholar
Hirose S, Kim S, Miyazaki H, Park YS, Murakami K. In vitro biosynthesis of human renin and identification of plasma inactive renin as an activation intermediate. J Biol Chem. 1985;260:16400–5.
Faust PL, Chirgwin JM, Kornfeld S. Renin, a secretory glycoprotein, acquires phosphomannosyl residues. J Cell Biol. 1987;105:1947–55.
Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, et al. Human prorenin has “gate and handle” regions for its non-proteolytic activation. J Biol Chem. 2003;278:22217–22.
Wu Z, Cappiello MG, Scott BB, Bukhtiyarov Y, McGeehan GM. Purification and characterization of recombinant human renin for X-ray crystallization studies. BMC Biochem. 2008;9:19.
Schwenk JM, Omenn GS, Sun Z, Campbell DS, Baker MS, Overall CM, et al. The Human Plasma Proteome Draft of 2017: Building on the Human Plasma PeptideAtlas from mass spectrometry and complementary assays. J Proteome Res. 2017;16:4299–310.
Akahane K, Umeyama H, Nakagawa S, Moriguchi I, Hirose S, Iizuka K, et al. Three-dimensional structure of human renin. Hypertension. 1985;7:3–12.
Blundell T, Sibanda BL, Pearl L. Three-dimensional structure, specificity and catalytic mechanism of renin. Nature. 1983;304:273–5.
Batenburg WW, Danser AH. (Pro)renin and its receptors: pathophysiological implications. Clin Sci. 2012;123:121–33.
Katz FH, Romfh P. Plasma aldosterone and renin activity during the menstrual cycle. J Clin Endocrinol Metab. 1972;34:819–21.
Sundsfjord JA. Plasma renin activity and aldosterone excretion during prolonged progesterone administration. Acta Endocrinol. 1971;67:483–90.
CAS Google Scholar
Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin. J Clin Investig. 2004;114:1128–35.
Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol. 2006;17:1950–61.
Yoshikawa A, Aizaki Y, Kusano K, Kishi F, Susumu T, Iida S, et al. The (pro)renin receptor is cleaved by ADAM19 in the Golgi leading to its secretion into extracellular space. Hypertens Res. 2011;34:599–605.
Yamash*ta K, Morimoto S, Seki Y, Watanabe D, Ichihara A. Serum-soluble (pro)renin receptor concentration as a biomarker for organ damage in primary aldosteronism. Hypertens Res. 2019;42:1951–60.
